BRPI0810208A2 - Combinação de terapias compreendendo inibidores p13k-alpha à base de quinoxalina para uso no tratamento do câncer. - Google Patents

Combinação de terapias compreendendo inibidores p13k-alpha à base de quinoxalina para uso no tratamento do câncer.

Info

Publication number
BRPI0810208A2
BRPI0810208A2 BRPI0810208-2A2A BRPI0810208A BRPI0810208A2 BR PI0810208 A2 BRPI0810208 A2 BR PI0810208A2 BR PI0810208 A BRPI0810208 A BR PI0810208A BR PI0810208 A2 BRPI0810208 A2 BR PI0810208A2
Authority
BR
Brazil
Prior art keywords
quinoxaline
therapies
understanding
combination
cancer treatment
Prior art date
Application number
BRPI0810208-2A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter Lamb
David Matthews
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of BRPI0810208A2 publication Critical patent/BRPI0810208A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0810208-2A2A 2007-04-11 2008-04-08 Combinação de terapias compreendendo inibidores p13k-alpha à base de quinoxalina para uso no tratamento do câncer. BRPI0810208A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92316407P 2007-04-11 2007-04-11
PCT/US2008/004570 WO2008127594A2 (en) 2007-04-11 2008-04-08 Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0810208A2 true BRPI0810208A2 (pt) 2014-10-21

Family

ID=39864581

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810208-2A2A BRPI0810208A2 (pt) 2007-04-11 2008-04-08 Combinação de terapias compreendendo inibidores p13k-alpha à base de quinoxalina para uso no tratamento do câncer.

Country Status (33)

Country Link
US (1) US8481001B2 (Direct)
EP (1) EP2139483B9 (Direct)
JP (2) JP5726515B2 (Direct)
KR (1) KR101586774B1 (Direct)
CN (2) CN101959516B (Direct)
AU (1) AU2008239668B2 (Direct)
BR (1) BRPI0810208A2 (Direct)
CA (1) CA2684056A1 (Direct)
CO (1) CO6140024A2 (Direct)
CR (1) CR11099A (Direct)
CY (1) CY1114608T1 (Direct)
DK (1) DK2139483T3 (Direct)
EA (1) EA019064B1 (Direct)
EC (1) ECSP099723A (Direct)
ES (1) ES2438998T3 (Direct)
GT (1) GT200900263A (Direct)
HR (1) HRP20131081T1 (Direct)
IL (1) IL201211A (Direct)
MA (1) MA31335B1 (Direct)
ME (1) ME00937B (Direct)
MX (1) MX2009010929A (Direct)
MY (1) MY150797A (Direct)
NI (1) NI200900184A (Direct)
NZ (1) NZ580009A (Direct)
PL (1) PL2139483T3 (Direct)
PT (1) PT2139483E (Direct)
RS (1) RS53020B (Direct)
SI (1) SI2139483T1 (Direct)
SV (1) SV2009003390A (Direct)
TN (1) TN2009000399A1 (Direct)
UA (1) UA98141C2 (Direct)
WO (1) WO2008127594A2 (Direct)
ZA (1) ZA200906765B (Direct)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ594630A (en) * 2005-10-07 2013-04-26 Exelixis Inc N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
GEP20115304B (en) * 2005-10-07 2011-10-10 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
HRP20130688T1 (en) * 2007-04-10 2013-09-30 Exelixis Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
PL2374802T3 (pl) * 2008-11-10 2014-09-30 Kyowa Hakko Kirin Co Ltd Inhibitor wytwarzania kinureniny
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
TW201139436A (en) 2010-02-09 2011-11-16 Exelixis Inc Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
TW201244719A (en) 2010-07-09 2012-11-16 Exelixis Inc Combinations of kinase inhibitors for the treatment of cancer
CA2812089C (en) 2010-09-14 2020-02-18 Exelixis Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
AU2011317675A1 (en) 2010-10-20 2013-05-02 Merck Serono S.A. Geneva Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)sulfonamides
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
CA2848724A1 (en) * 2011-09-14 2013-03-21 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
AU2012318580A1 (en) * 2011-10-04 2014-05-22 Gilead Calistoga Llc Novel quinoxaline inhibitors of PI3K
WO2013056067A1 (en) 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
RU2014120792A (ru) * 2011-10-28 2015-12-10 Новартис Аг Способ лечения стромальных опухолей желудочно-кишечного тракта
PE20141794A1 (es) * 2011-11-01 2014-12-17 Exelixis Inc N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas
WO2013067306A1 (en) * 2011-11-02 2013-05-10 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
CA2860051A1 (en) 2011-12-27 2013-07-04 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
JP6077642B2 (ja) 2012-04-10 2017-02-08 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用
WO2014028479A1 (en) 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Quinoxaline derivatives as gpr6 modulators
WO2015043398A1 (zh) 2013-09-30 2015-04-02 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
MX381304B (es) 2013-10-16 2025-03-12 Shanghai Yingli Pharm Co Ltd Compuesto heterocíclico fusionado, método de preparación del mismo, composición farmacéutica, y usos del mismo.
US10179783B2 (en) 2014-02-14 2019-01-15 Taketa Pharmaceutical Company Limited Tetrahydropyridopyrazines as modulators of GPR6
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2019119206A1 (en) * 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515885A (ja) * 2003-01-17 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の処置のための併用療法
BRPI0615233A2 (pt) * 2005-08-26 2011-05-10 Serono Lab derivados de pirazina e uso dos mesmos como inibidores p13k
NZ594630A (en) * 2005-10-07 2013-04-26 Exelixis Inc N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
GEP20115304B (en) * 2005-10-07 2011-10-10 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
ZA200904857B (en) * 2007-02-22 2010-09-29 Merck Serono Sa Quinoxaline compounds and use thereof
HRP20130688T1 (en) * 2007-04-10 2013-09-30 Exelixis Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
JP4623164B2 (ja) * 2008-08-21 2011-02-02 セイコーエプソン株式会社 プロジェクタ

Also Published As

Publication number Publication date
US8481001B2 (en) 2013-07-09
CR11099A (es) 2010-01-19
KR101586774B1 (ko) 2016-01-19
IL201211A (en) 2015-09-24
WO2008127594A3 (en) 2009-04-30
HRP20131081T1 (hr) 2013-12-20
PT2139483E (pt) 2013-12-27
ZA200906765B (en) 2010-05-26
NZ580009A (en) 2012-06-29
AU2008239668B2 (en) 2013-11-07
AU2008239668A1 (en) 2008-10-23
CA2684056A1 (en) 2008-10-23
PL2139483T3 (pl) 2014-02-28
RS53020B (sr) 2014-04-30
EA019064B1 (ru) 2013-12-30
CY1114608T1 (el) 2016-10-05
CN101959516A (zh) 2011-01-26
EA200970935A1 (ru) 2010-04-30
MY150797A (en) 2014-02-28
ECSP099723A (es) 2010-03-31
SI2139483T1 (sl) 2013-11-29
IL201211A0 (en) 2010-05-31
UA98141C2 (ru) 2012-04-25
MX2009010929A (es) 2010-01-20
EP2139483B9 (en) 2014-05-21
WO2008127594A2 (en) 2008-10-23
ME00937B (me) 2012-06-20
MA31335B1 (fr) 2010-04-01
JP5726515B2 (ja) 2015-06-03
JP2010523669A (ja) 2010-07-15
HK1140141A1 (en) 2010-10-08
GT200900263A (es) 2014-01-15
NI200900184A (es) 2011-09-08
ES2438998T3 (es) 2014-01-21
JP2014074031A (ja) 2014-04-24
CN101959516B (zh) 2013-05-08
TN2009000399A1 (fr) 2010-12-31
EP2139483B1 (en) 2013-09-18
KR20100019436A (ko) 2010-02-18
US20110123434A1 (en) 2011-05-26
CN103202842A (zh) 2013-07-17
CO6140024A2 (es) 2010-03-19
SV2009003390A (es) 2010-05-21
EP2139483A2 (en) 2010-01-06
DK2139483T3 (da) 2014-01-13

Similar Documents

Publication Publication Date Title
BRPI0810208A2 (pt) Combinação de terapias compreendendo inibidores p13k-alpha à base de quinoxalina para uso no tratamento do câncer.
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0813356A2 (pt) Inibidores de proteína quinase e métodos para uso dos mesmos
BR112013033940A2 (pt) terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
BRPI0812450A2 (pt) derivados de indazol policíclicos e seu uso como inibidores de erk para o tratamento de câncer
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
BRPI0820556A2 (pt) Bactéria e métodos para uso das mesmas
BRPI0906444A2 (pt) Compostos de 4-piridinona e seu uso para câncer
BRPI0914007A2 (pt) anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0719195A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas
BRPI0813216A2 (pt) Inibidores de proteínas cinases e métodos para usá-los.
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BRPI0810524A2 (pt) Derivado de (aza)indol e uso do mesmo para propósitos médicos
BR112012004970A2 (pt) inibidores de jak2 e seu uso para o tratamento de doenças mieloproliferativas e câncer
BRPI0812944A2 (pt) Derivados de 6-(pirrolopiridinil)pirimidin-2-ilamina e o uso dos mesmos para o tratamento de câncer e aids
BRPI0813828A2 (pt) Compostos antimicrobianos, a síntese dos mesmos e o uso dos mesmos para o tratamento de infecções em mamíferos
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BRPI0919794A2 (pt) dispositivo para uso intracorpóreo, e, composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]